The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML). The main questions it aims to answer are:
* Are there new ways to speed up discovery of better treatments for AML patients using AML cells from individual from patients in special mice that can accept human tissue? * Do these mice show treatment responses that are similar to the individual AML patient from whom cells were derived?
Participants with AML who are taking standard of care treatment of venetoclax and azacitidine will be asked to donate blood and bone marrow samples for this study.
Age 18 years and above
Patients with suspicion of AML requiring screening procedures
Documented diagnosis of AML by WHO Classification and/or International Consensus Classification.
Regardless of the number and type of prior lines of therapy or eligibility for allogeneic stem cell transplantation.
None
Clinical Hub for Interventional Research (CHOIR)
Lead sponsor
Cancer Institute NSW
Collaborator
The University of New South Wales
Collaborator
Australian National University
Collaborator